Acute Med. 2025;24(4):168-174. doi: 10.52964/AMJA.1024.
ABSTRACT
BACKGROUND: Angioedema is the development of non-pitting edema of the skin and mucosal tissues of the oropharynx, upper respiratory tract, and the gastrointestinal tract. Given the potential for airway compromise, the treatment strategy usually involves a broad approach by addressing multiple underlying possible pathologies simultaneously without knowing the exact mechanism. This is a common and often necessary approach when managing a critically ill patient with incomplete information. Although the current research on TXA use in angioedema centers on ACE-I induced mechanisms, the authors frequently see it used in undifferentiated angioedema.
METHODS: This is a retrospective comparative study evaluating the effect of intravenous TXA administration to treat acute angioedema when compared to usual treatment. Hospital admissions, repeat ED visits specifically related to angioedema within 30 days, 30-day all-cause mortality, and need for an advanced airway were assessed as outcomes.
RESULTS: After applying inclusion and exclusion criteria, 562 ED encounters were identified for chart review. Matched ED encounters comparing TXA use and no TXA use were well balanced. No statistically significant difference was identified when using TXA or not for angioedema when examining the outcome variables.
CONCLUSION: No significant differences were seen between the groups when evaluating ED revisits related to angioedema, hospital admission, the need for an advanced airway, and 30-day all-cause mortality. Prospective analysis of TXA in angioedema is needed to clarify its role in acute treatment.
PMID:42462217 | DOI:10.52964/AMJA.1024
